These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 26369501)

  • 1. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
    Colhoun HM; Robinson JG; Farnier M; Cariou B; Blom D; Kereiakes DJ; Lorenzato C; Pordy R; Chaudhari U
    BMC Cardiovasc Disord; 2014 Sep; 14():121. PubMed ID: 25240705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.
    Lepor NE; Contreras L; Desai C; Kereiakes DJ
    Rev Cardiovasc Med; 2014; 15(4):290-307; quiz 308-9. PubMed ID: 25662924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.